NEW YORK, April 21, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
A complete and practical analysis of Ophthalmology Drugs packed with facts, figures and forecasts for launched and late-stage products
The US$14 billion global ophthalmology sector faces both commercial challenge and clinical opportunity, and this report answers key questions:
Why are we interested in chronic eye diseases?
Driven by ageing populations, which markets are expected to see the highest growth in the 65+ age groups?
Which sectors of the market are anticipated to contract by value over the next five years?
What new products will be launched over the next 5 years and what impact will they have on the market?
Which companies are set to improve their market share?
What novel products are in development for Wet Age-related Macular Degeneration (AMD)?
Dry AMD – large unmet clinical need, but what is the potential?
What potential benefits does Bayer's VEGF Trap?Eye Regeneron have over existing treatments?
Merck's NDA for Saflutan was submitted to FDA in March 2011 – what impact on the market could this product have?
Why are new treatments needed for dry eye?
Sight preservation in chronic eye disease is a high yielding, valuable and expanding sector in developed and emerging markets
AGE-RELATED MACULAR DEGENERATION
The market for drugs used to treat wet age-related macular degeneration (AMD) is estimated to be worth US$3.3 billion. There are relatively few players and an increasing patient pool; continued growth is expected over the medium term
|SOURCE S ....... 118|
Copyright©2010 PR Newswire.
All rights reserved